查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球生物製品市场评估:按产品,应用,药物类别,采购方式,分销管道,地区,机会和预测（2017-2031）
市场调查报告书
商品编码
1417589

全球生物製品市场评估:按产品,应用,药物类别,采购方式,分销管道,地区,机会和预测（2017-2031）

Biologics Market Assessment, By Product By Application By Drug Classification, By Mode of Purchase By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 242 Pages | 商品交期: 3-5个工作天内

价格

预计2023年全球生物製品市场规模将达4,013.4亿美元，2031年将达6,957.9亿美元，2024-2031年预测期间内复合年增长率为7.12%。慢性病的盛行率和诊断率不断上升，对先进的诊断和治疗药物产生了巨大的需求，从而推动了全球生物製品市场的发展。这些专门的药物经过基因改造，以针对引起发炎的免疫系统的特定成分。随着 COVID-19 疾病的出现，世界各国政府正在采取措施加强医疗产业并确保生物製剂的供应。

同时，科学家和研究人员正在探索不同的物种和表现系统，以提高生物製剂的效率。此外，许多製药公司正在进行旨在提高关节炎口服药物有效性的研究和开发。由于小分子药物研发的生产力下降，预计未来几年生物製剂市场将出现重大飞跃。这些製药公司正在积极开发各种生物製剂，以维持其市场主导地位。随着治疗克隆氏症和类风湿性关节炎等疾病的口服药物变得更加有效，预计将有更多的中度疾病患者转向新品牌的治疗。此外，这些新化合物为对传统治疗有抵抗力的患者提供了替代治疗，并且通常表现出卓越的安全性和有效性。

慢性病盛行率高

全球生物製品市场受到慢性病高盛行率的显着影响。癌症、糖尿病、自体免疫疾病和心血管疾病等慢性疾病在世界各地变得越来越普遍。生物製剂，即从生物体中提取的药物，已成为许多此类疾病的重要治疗选择。这些复杂的分子提供标靶治疗，并且通常比传统药物更有效且副作用更少。

例如，根据世界卫生组织（WHO）2023年9月发布的报告，每年约有4100万人死于非传染性疾病（NCD），占全球死亡总人数的74%。到 ％。每年，大约有 1700 万人在 70 岁之前死于非传染性疾病，其中 86% 的过早死亡发生在全球。全球每年有超过 4,100 万人死于慢性病。其中，心血管疾病每年导致1790万人死亡，其次是癌症、糖尿病和呼吸系统疾病。这四类疾病合计占慢性病死亡人数的 80%。慢性病的流行正在推动诊断和治疗的进步。

更加重视研究和开发

市场扩张是由对研发活动的日益重视所推动的，预计将为生物製品市场的成长提供良好的前景。此外，科学家和研究人员正在探索不同的物种和表现系统，以提高生物製剂的生产力。一些製药公司从事研究和开发活动，旨在提高口服药物治疗类风湿性关节炎和克隆氏症等疾病的有效性。此外，加速药物审批和推出也支持了市场成长轨迹。

例如，2023年1月，lecanemab透过美国FDA加速审批途径获准用于治疗阿兹海默症。2022年6月，Alnylam 的 Amvtra 获得 FDA 批准，这是一种 RNAi 疗法，用于治疗与遗传性转甲状腺素蛋白介导的淀粉样变性相关的多发性神经病变。

各大企业加大投资力度

全球生物製品市场主要参与者的投资持续激增，显示该行业的成长和潜力。各大製药公司、生技公司和研究机构都在生物製剂的研究、开发和製造方面投入大量资金。这些注资旨在加强创新、扩大产品组合併改善製造技术，最终满足对先进个人化医疗解决方案不断增长的需求。

竞争格局正在迅速演变，该公司计划推出新的生物製剂，重点关注癌症、自体免疫疾病和传染病等多种治疗领域。不断增长的投资趋势表明业界对市场光明的未来充满信心，推动突破性进展并改善治疗方案以应对世界医疗挑战。

本报告研究和分析了全球生物製品市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章 COVID-19对全球生物製品市场的影响

第 4 章执行摘要

第五章 全球生物製品市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按产品
    • 单克隆抗体
    • 重组荷尔蒙/蛋白质
    • 疫苗接种
    • 基于细胞的生物製剂
    • 基于基因的生物製剂
    • 治疗酵素
    • 其他
  • 按用途
    • 感染
    • 癌症
    • 自身免疫性疾病
    • 心血管
    • 血液病
    • 其他
  • 按药品分类
    • 品牌药品
    • 仿製药
  • 按购买方式
    • 处方药
    • 非处方药
  • 按分销渠道
    • 医院药房
    • 零售药店
    • 网上药店
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第六章 全球生物製品市场展望：按地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 按产品
    • 按用途
    • 按药品分类
    • 按购买方式
    • 按分销渠道
    • 美国
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第 7 章 市场测绘（2023）

  • 按产品
  • 按用途
  • 按药品分类
  • 按购买方式
  • 按分销渠道
  • 按地区

第八章 宏观环境与产业结构

  • 供需分析
  • 进出口分析 - 数量和价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第九章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第十章 监理框架与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十一章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第12章价格分析

第十三章案例研究

第十四章 主要公司展望

  • F. Hoffmann La-Roche Ltd.
  • Samsung Biologics
  • Amgen Inc.
  • Novo Nordisk A/S
  • AbbVie Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Celltrion Healthcare Co., Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

第十五章 战略建议

第十六章 关于我们公司、免责声明

Product Code: MX10883

Global biologics market size was valued at USD 401.34 billion in 2023, and is expected to reach USD 695.79 billion in 2031, with a CAGR of 7.12% for the forecast period between 2024 and 2031F. The increasing incidence and diagnosis of chronic diseases have created a significant demand for advanced diagnostics and treatment medications, consequently propelling the global biologics market. These specialized drugs have been genetically altered to target specific components of the immune system that trigger inflammation. With the emergence of coronavirus diseases, governments worldwide are taking measures to fortify the healthcare industry and ensure the availability of biologics.

Simultaneously, scientists and researchers are exploring different species and expression systems to enhance the efficiency of biological products. Moreover, numerous pharmaceutical companies are engaged in research and development efforts aimed at enhancing the effectiveness of oral medications for arthritis. Given the decline in productivity in small molecule medication research and development, a substantial surge in the biologics market is anticipated in the coming years. These pharmaceutical firms are actively pursuing the development of various biologic medications to sustain their market dominance. As oral medications for conditions like Crohn's disease and rheumatoid arthritis become more effective, it is predicted that a larger number of moderately affected patients will transition towards newly branded therapies. Additionally, these new compounds provide therapeutic alternatives for patients who have previously shown resistance to traditional treatments, often displaying superior safety and efficacy.

High Prevalence of Chronic Diseases

The global biologics market is witnessing a significant impact due to the high prevalence of chronic diseases. Chronic conditions like cancer, diabetes, autoimmune disorders, and cardiovascular diseases are increasingly becoming prevalent globally. Biologics, which are medicinal products derived from living organisms, have emerged as a critical treatment option for many of these conditions. These complex molecules offer targeted therapies, often with fewer side effects and greater efficacy than traditional pharmaceuticals.

For instance, as per the World Health Organization's report in September 2023, approximately 41 million individuals succumb annually to non-communicable diseases (NCD), representing 74% of the total global deaths. Each year, roughly 17 million people perish from NCDs before reaching the age of 70, with 86% of these untimely fatalities occurring on a global scale. Over 41 million individuals globally succumb to chronic diseases annually. Among these, cardiovascular disease leads, causing 17.9 million deaths per year, followed by cancer, diabetes, and respiratory disorders. Together, these four categories account for 80% of all fatalities attributed to chronic diseases. The prevalence of chronic diseases has spurred the advancement of diagnostics and treatments. Biologics, genetically engineered medications, and target specific components of the immune system are responsible for inflammation.

Increasing Emphasis on Research and Development

The expansion of the market is being driven by the increasing emphasis on research and development activities, which is expected to create advantageous prospects for biologics market growth. Moreover, scientists and researchers are exploring various species and expression systems to enhance the productivity of biological products. Several pharmaceutical companies are engaged in research and development activities aimed at improving the effectiveness of oral medications for conditions like rheumatoid arthritis and Crohn's disease. Furthermore, the escalating rate of drug approvals and introductions will continue to accelerate the growth trajectory of the market.

For instance, as an example, in January 2023, Lecanemab received approval from the U.S. FDA via its accelerated approval pathway, specifically intended for addressing Alzheimer's Disease. In June 2022, Alnylam Pharmaceuticals, Inc. obtained FDA approval for its RNAi therapeutic, AMVUTTRA, designed for treating the Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

Growing Investments by Key Players

The global biologics market continues to witness a surge in investments by key players, indicative of the sector's growth and potential. Major pharmaceutical companies, biotech firms, and research institutions are channeling substantial investments into research, development, and manufacturing of biologics. The financial commitment aims to bolster innovation, expand product portfolios, and enhance manufacturing technologies, ultimately meeting the rising demand for advanced and personalized healthcare solutions.

The competitive landscape is evolving rapidly as companies are planning to introduce novel biologics, focusing on diverse therapeutic areas like oncology, autoimmune diseases, and infectious diseases. The growing investment trend signifies the industry's confidence in the market's promising future, fostering groundbreaking advancements and improved treatment options for global healthcare challenges. For Instance, in March 2023, Novartis announced the intention of its division, Sandoz to allocate roughly USD 400 million towards establishing a biologics manufacturing plant situated in Slovenia. During March 2023, Eli Lilly disclosed its proposal to invest USD 500 million into expanding its current 500,000 sq. ft. biologics manufacturing site in Limerick.

Technological Advancements

The global biologics market has witnessed remarkable technological advancements, revolutionizing the landscape of medicine and healthcare. Innovations in biotechnology, particularly in areas like genetic engineering, monoclonal antibodies, and recombinant DNA technology, have significantly enhanced the development and production of biologics industry.

Advanced techniques in cell culture systems, gene editing (like CRISPR), and bioprocessing have streamlined the manufacturing of complex biological molecules. Furthermore, the emergence of personalized medicine has driven a shift towards more tailored and effective treatments, utilizing biologics designed to target specific patient populations. The progress has led to the development of novel biologics, including therapeutic proteins, vaccines, and monoclonal antibodies, fostering breakthroughs in treating various diseases like cancer, autoimmune disorders, and infectious diseases.

For Instance, in February 2022 CARVYKTI, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson obtained approval from the US Food and Drug Administration (FDA) for sale. The biologic medication is designated for individuals with relapsed or refractory multiple myeloma (RRMM) who have undergone four prior lines of therapy, which may include proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody treatments.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global biologics market. Biologics are complex, large-molecule drugs used to treat a variety of diseases, including autoimmune disorders, cancer, and infectious diseases. The pandemic disrupted supply chains and manufacturing processes, leading to production delays and shortages of some biologics. Additionally, the increased focus on vaccine development and monoclonal antibody therapies to combat the virus diverted resources and attention from other biologic drug development efforts.

On the contrary, the pandemic has highlighted the importance of biotechnology and accelerated innovation in the field. The rapid development of mRNA vaccines, such as the Pfizer-BioNTech and Moderna vaccines, showcased the potential of biologics in responding to infectious diseases. Furthermore, the pandemic has driven investment in research and development of biologics, leading to advancements in bioprocessing and manufacturing technologies. During April 2022, GSK, a British multinational pharmaceutical and biotechnology company, together with SK bioscience, presented a biologics license application for SKYCovione, a COVID-19 vaccine candidate based on recombinant proteins, to the Korean Ministry of Food and Drug Safety (KMFDS).

Key Players Landscape and Outlook

Prominent industry stakeholders are allocating significant funds to research and development endeavors, aiming to diversify their product portfolios, thereby stimulating the expansion of the global biologics market. The market participants are implementing various strategic measures to enhance their global presence, including pivotal actions such as launching new products, engaging in mergers and acquisitions, forming contractual agreements, amplifying investments, and fostering collaborations with other organizations. In the competitive landscape of the biologics sector, companies must provide cost-effective offerings to broaden their scope and endure in an intensifying, competitive, and burgeoning market environment.

For Instance, the FDA granted approval to Leqembi (lecanemab-irmb) through the Accelerated Approval pathway in January 2023 for addressing Alzheimer's disease. The medication diminishes amyloid-B plaques and moderately retards mild cognitive decline in individuals with early-stage Alzheimer's disease.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Biologics Market

4. Executive Summary

5. Global Biologics Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Product
    • 5.2.1. Monoclonal Antibodies
    • 5.2.2. Recombinant Hormones/Proteins
    • 5.2.3. Vaccines
    • 5.2.4. Cellular Based Biologics
    • 5.2.5. Gene-Based Biologics
    • 5.2.6. Therapeutic Enzymes
    • 5.2.7. Others
  • 5.3. By Application
    • 5.3.1. Infectious Diseases
    • 5.3.2. Cancer
    • 5.3.3. Autoimmune Diseases
    • 5.3.4. Cardiovascular
    • 5.3.5. Hematological Disorders
    • 5.3.6. Others
  • 5.4. By Drug Classification
    • 5.4.1. Branded Drugs
    • 5.4.2. Generic Drugs
  • 5.5. By Mode of Purchase
    • 5.5.1. Prescription Drugs
    • 5.5.2. Over-the-counter Drugs
  • 5.6. By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies
    • 5.6.3. Online Pharmacies
    • 5.6.4. Others
  • 5.7. By Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. South America
    • 5.7.5. Middle East & Africa
  • 5.8. By Company Market Share (%), 2023

6. Global Biologics Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Product
      • 6.1.2.1. Monoclonal Antibodies
      • 6.1.2.2. Recombinant Hormones/Proteins
      • 6.1.2.3. Vaccines
      • 6.1.2.4. Cellular Based Biologics
      • 6.1.2.5. Gene-Based Biologics
      • 6.1.2.6. Therapeutic Enzymes
      • 6.1.2.7. Others
    • 6.1.3. By Application
      • 6.1.3.1. Infectious Diseases
      • 6.1.3.2. Cancer
      • 6.1.3.3. Autoimmune Diseases
      • 6.1.3.4. Cardiovascular
      • 6.1.3.5. Hematological Disorders
      • 6.1.3.6. Others
    • 6.1.4. By Drug Classification
      • 6.1.4.1. Branded Drugs
      • 6.1.4.2. Generic Drugs
    • 6.1.5. By Mode of Purchase
      • 6.1.5.1. Prescription Drugs
      • 6.1.5.2. Over-the-counter Drugs
    • 6.1.6. By Distribution Channel
      • 6.1.6.1. Hospital Pharmacies
      • 6.1.6.2. Retail Pharmacies
      • 6.1.6.3. Online Pharmacies
      • 6.1.6.4. Others
    • 6.1.7. United States*
      • 6.1.7.1. By Product
      • 6.1.7.1.1. Monoclonal Antibodies
      • 6.1.7.1.2. Recombinant Hormones/Proteins
      • 6.1.7.1.3. Vaccines
      • 6.1.7.1.4. Cellular Based Biologics
      • 6.1.7.1.5. Gene-Based Biologics
      • 6.1.7.1.6. Therapeutic Enzymes
      • 6.1.7.1.7. Others
      • 6.1.7.2. By Application
      • 6.1.7.2.1. Infectious Diseases
      • 6.1.7.2.2. Cancer
      • 6.1.7.2.3. Autoimmune Diseases
      • 6.1.7.2.4. Cardiovascular
      • 6.1.7.2.5. Hematological Disorders
      • 6.1.7.2.6. Others
      • 6.1.7.3. By Drug Classification
      • 6.1.7.3.1. Branded Drugs
      • 6.1.7.3.2. Generic Drugs
      • 6.1.7.4. By Mode of Purchase
      • 6.1.7.4.1. Prescription Drugs
      • 6.1.7.4.2. Over-the-counter Drugs
      • 6.1.7.5. By Distribution Channel
      • 6.1.7.5.1. Hospital Pharmacies
      • 6.1.7.5.2. Retail Pharmacies
      • 6.1.7.5.3. Online Pharmacies
      • 6.1.7.5.4. Others
      • 6.1.7.6. By Region
      • 6.1.7.6.1. North America
      • 6.1.7.6.2. Europe
      • 6.1.7.6.3. Asia Pacific
      • 6.1.7.6.4. South America
      • 6.1.7.6.5. Middle East & Africa
      • 6.1.7.7. Canada
      • 6.1.7.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Product
  • 7.2. By Application
  • 7.3. By Drug Classification
  • 7.4. By Mode of Purchase
  • 7.5. By Distribution Channel
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. F. Hoffmann La-Roche Ltd.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Samsung Biologics
  • 14.3. Amgen Inc.
  • 14.4. Novo Nordisk A/S
  • 14.5. AbbVie Inc.
  • 14.6. Sanofi
  • 14.7. Johnson & Johnson Services, Inc.
  • 14.8. Celltrion Healthcare Co., Ltd.
  • 14.9. Bristol-Myers Squibb Company
  • 14.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Biologics Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Biologics Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 6. Global Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 7. Global Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Biologics Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 11. North America Biologics Market Share (%), By Product, 2017-2031F
  • Figure 12. North America Biologics Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 14. North America Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 15. North America Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16. North America Biologics Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 19. United States Biologics Market Share (%), By Product, 2017-2031F
  • Figure 20. United States Biologics Market Share (%), By Application, 2017-2031F
  • Figure 21. United States Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 22. United States Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 23. United States Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24. Canada Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 26. Canada Biologics Market Share (%), By Product, 2017-2031F
  • Figure 27. Canada Biologics Market Share (%), By Application, 2017-2031F
  • Figure 28. Canada Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 29. Canada Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 30. Canada Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. Mexico Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 33. Mexico Biologics Market Share (%), By Product, 2017-2031F
  • Figure 34. Mexico Biologics Market Share (%), By Application, 2017-2031F
  • Figure 35. Mexico Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 36. Mexico Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 37. Mexico Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38. Europe Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 40. Europe Biologics Market Share (%), By Product, 2017-2031F
  • Figure 41. Europe Biologics Market Share (%), By Application, 2017-2031F
  • Figure 42. Europe Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 43. Europe Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 44. Europe Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45. Europe Biologics Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. Germany Biologics Market Share (%), By Product, 2017-2031F
  • Figure 49. Germany Biologics Market Share (%), By Application, 2017-2031F
  • Figure 50. Germany Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 51. Germany Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 52. Germany Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53. France Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 55. France Biologics Market Share (%), By Product, 2017-2031F
  • Figure 56. France Biologics Market Share (%), By Application, 2017-2031F
  • Figure 57. France Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 58. France Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 59. France Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Italy Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 62. Italy Biologics Market Share (%), By Product, 2017-2031F
  • Figure 63. Italy Biologics Market Share (%), By Application, 2017-2031F
  • Figure 64. Italy Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 65. Italy Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 66. Italy Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. United Kingdom Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 69. United Kingdom Biologics Market Share (%), By Product, 2017-2031F
  • Figure 70. United Kingdom Biologics Market Share (%), By Application, 2017-2031F
  • Figure 71. United Kingdom Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 72. United Kingdom Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 73. United Kingdom Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Russia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 76. Russia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 77. Russia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 78. Russia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 79. Russia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 80. Russia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Netherlands Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 83. Netherlands Biologics Market Share (%), By Product, 2017-2031F
  • Figure 84. Netherlands Biologics Market Share (%), By Application, 2017-2031F
  • Figure 85. Netherlands Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 86. Netherlands Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 87. Netherlands Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Spain Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Spain Biologics Market Share (%), By Product, 2017-2031F
  • Figure 91. Spain Biologics Market Share (%), By Application, 2017-2031F
  • Figure 92. Spain Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 93. Spain Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 94. Spain Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Turkey Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 97. Turkey Biologics Market Share (%), By Product, 2017-2031F
  • Figure 98. Turkey Biologics Market Share (%), By Application, 2017-2031F
  • Figure 99. Turkey Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 100. Turkey Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 101. Turkey Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. Poland Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 104. Poland Biologics Market Share (%), By Product, 2017-2031F
  • Figure 105. Poland Biologics Market Share (%), By Application, 2017-2031F
  • Figure 106. Poland Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 107. Poland Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 108. Poland Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109. South America Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 111. South America Biologics Market Share (%), By Product, 2017-2031F
  • Figure 112. South America Biologics Market Share (%), By Application, 2017-2031F
  • Figure 113. South America Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 114. South America Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 115. South America Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. South America Biologics Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 119. Brazil Biologics Market Share (%), By Product, 2017-2031F
  • Figure 120. Brazil Biologics Market Share (%), By Application, 2017-2031F
  • Figure 121. Brazil Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 122. Brazil Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 123. Brazil Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Argentina Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 126. Argentina Biologics Market Share (%), By Product, 2017-2031F
  • Figure 127. Argentina Biologics Market Share (%), By Application, 2017-2031F
  • Figure 128. Argentina Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 129. Argentina Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 130. Argentina Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Asia-Pacific Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 133. Asia-Pacific Biologics Market Share (%), By Product, 2017-2031F
  • Figure 134. Asia-Pacific Biologics Market Share (%), By Application, 2017-2031F
  • Figure 135. Asia-Pacific Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 136. Asia-Pacific Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 137. Asia- Pacific Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Asia-Pacific Biologics Market Share (%), By Country, 2017-2031F
  • Figure 139. India Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 141. India Biologics Market Share (%), By Product, 2017-2031F
  • Figure 142. India Biologics Market Share (%), By Application, 2017-2031F
  • Figure 143. India Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 144. India Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 145. India Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. China Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 148. China Biologics Market Share (%), By Product, 2017-2031F
  • Figure 149. China Biologics Market Share (%), By Application, 2017-2031F
  • Figure 150. China Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 151. China Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 152. China Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153. Japan Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 155. Japan Biologics Market Share (%), By Product, 2017-2031F
  • Figure 156. Japan Biologics Market Share (%), By Application, 2017-2031F
  • Figure 157. Japan Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 158. Japan Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 159. Japan Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160. Australia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 162. Australia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 163. Australia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 164. Australia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 165. Australia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 166. Australia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167. Vietnam Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 169. Vietnam Biologics Market Share (%), By Product, 2017-2031F
  • Figure 170. Vietnam Biologics Market Share (%), By Application, 2017-2031F
  • Figure 171. Vietnam Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 172. Vietnam Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 173. Vietnam Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. South Korea Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 176. South Korea Biologics Market Share (%), By Product, 2017-2031F
  • Figure 177. South Korea Biologics Market Share (%), By Application, 2017-2031F
  • Figure 178. South Korea Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 179. South Korea Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 180. South Korea Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. Indonesia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. Indonesia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 184. Indonesia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 185. Indonesia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 186. Indonesia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 187. Indonesia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188. Philippines Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 190. Philippines Biologics Market Share (%), By Product, 2017-2031F
  • Figure 191. Philippines Biologics Market Share (%), By Application, 2017-2031F
  • Figure 192. Philippines Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 193. Philippines Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 194. Philippines Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195. Middle East & Africa Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 197. Middle East & Africa Biologics Market Share (%), By Product, 2017-2031F
  • Figure 198. Middle East & Africa Biologics Market Share (%), By Application, 2017-2031F
  • Figure 199. Middle East & Africa Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 200. Middle East & Africa Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 201. Middle East & Africa Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202. Middle East & Africa Biologics Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 205. Saudi Arabia Biologics Market Share (%), By Product, 2017-2031F
  • Figure 206. Saudi Arabia Biologics Market Share (%), By Application, 2017-2031F
  • Figure 207. Saudi Arabia Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 208. Saudi Arabia Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 209. Saudi Arabia Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210. UAE Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 212. UAE Biologics Market Share (%), By Product, 2017-2031F
  • Figure 213. UAE Biologics Market Share (%), By Application, 2017-2031F
  • Figure 214. UAE Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 215. UAE Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 216. UAE Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217. South Africa Biologics Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Biologics Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 219. South Africa Biologics Market Share (%), By Product, 2017-2031F
  • Figure 220. South Africa Biologics Market Share (%), By Application, 2017-2031F
  • Figure 221. South Africa Biologics Market Share (%), By Drug Classification, 2017-2031F
  • Figure 222. South Africa Biologics Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 223. South Africa Biologics Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Drug Classification Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Mode of Purchase Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023